Worldwide, 1 billion people are living with mental health conditions plus a further 50 million with dementia. The global trend of ageing populations will continue to increase the numbers of those impacted either directly or indirectly.
Society is increasingly becoming aware, accepting and talking about mental health conditions. Private and Public funding of effective care is needing to match these changes.
The global research community is increasing the availability of effective therapeutic and non-therapeutic options through service improvements, next generation products and the safe use of existing drugs for multiple conditions. However, clinical trials remain expensive and take longer than needed.
Global clinical trials, across all therapeutic areas, are projected to cost over £150 billion per annum by 2024. On average, the launch of each drug costs an estimated £2 billion. Trial costs continue to rise due to more complex drugs, increased complexity of trial methods and larger, multi-continent trials to achieve regulatory clearance.
For Central Nervous System drugs, trial costs tend to be higher as they have a greater failure rate at a later stage especially when introducing first-in-class therapeutics with an unprecedented mode of action.
Lengthy drug approval procedures can result in drug trials of 13-15 years. However, with patents only lasting 20 years and exclusivity for 7 years, limited time exists for a pharmaceutical company to re-gain their investment.
It is estimated that reducing a development programme by 18 months can increase the value of a drug by £150 million and will provide quicker therapeutic benefits to patients.
Future treatment and care provision need to be more effective and efficient to meet the projected demand. This can only be achieved by combining improved technologies, efficient clinical trials, new drug applications and the development of precision psychiatry models.
Decision making, based upon precision psychiatry models, will be dependent upon complex patient-level datasets that combine remote and continuous clinical data, genetic data and brain images. These models will need to be continuously assessed and improved with updates of real-world data.
Akrivia Health can support organisations in delivering this goal from early stage drug discovery through to post launch service and drug evaluation.
Early Stage Drug Discovery
Market Access and Sales Tracking
Clinical Trial Revenue
Service Evaluation and Quality Improvement audits
Patient and Site Recruitment and Retention
Post Launch Evaluation and Pharma-covigilence
Data: The Difference
We have worked with our NHS Network Partners to develop the world’s largest specialist mental health and dementia clinical dataset. Over 2.7 million de-identified patient records are updated on a regular basis.
Our longitudinal dataset includes diagnosis, medications, outcomes and care plans covering 10 years. We continue to combine additional data sets, such as the UK BioBank, to enable precision psychiatry models to be developed.
Over the last 5 years, our team has been using Natural Language Processing and AI to generate structured data out of de-identified psychiatry clinical records. The clinical notes, which comprise 70-80% of the information available, are being turned into 440 billion data points.
We believe that data in this multi-factorial disease area is only useful if its context can be understood and is made easily available.
Supporting the Future of Mental Health
It is the right time to support the rapid advance in the development of mental health and dementia treatments using real world evidence data and precision psychiatry models. Akrivia Health’s clinical annotators and AI scientists have developed a secure, data platform that can support clinical trials, research and service improvement. We believe that the change in trajectory required can only be achieved when the global community works in collaboration.
Our platform enables registered Network users to securely work with de-identified data from 2.7 million patients from across the UK. Data is managed by Akrivia Health under an agreed set of Information Governance guidelines that are delivered through audited processes.
Any research or modelling conducted contains statistical or aggregate data as per NHS standards ISB 1523.Read More
In partnership with the Department of Psychiatry, University of Oxford, our AI scientists and clinical annotators support clients to better understand what de-identified data is available via the platform.
The team’s specialist knowledge means that they can advise on the most effective ways of structuring and interpreting data, and developing precision psychiatry models to answer specific questions.Read More
Our global, collaborative community encourages researchers and clinicians in healthcare organisations, academic institutions and the life sciences industry to learn and discover from one another.
The community shares innovation, service improvements and research outcomes, to advance drug research and service development through networking and training events.
We encourage patients to become involved in research studies and clinical trials so researchers can better understand real world issues and determine how they can be overcome.Read more